

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>

17th July 2026

Company:	Chordia Therapeutics Inc
Representative:	Chief Executive Officer Hiroshi Miyake (Security Code: 190A TSE Growth Market)
Contact:	Chief Financial Officer Masaru Okatani
MAIL :	info@chorditherapeutics.com

Notice of Receipt of Grant

Chordia Therapeutics Inc (Head Office: Fujisawa City, Kanagawa Prefecture; CEO: Hiroshi Miyake, “Chordia”) announced that it will receive a grant for the fourth quarter of the fiscal year ending August 31, 2026 (June 1, 2026 - August 31, 2026).

1. Details of the grant income

Chordia today announced that it has entered into a subcontract research and development agreement with Kyoto University, a national university corporation, for the “Non-clinical study of novel therapeutic agents for refractory tumors with RNA splicing mutations” under the project of “Research Project for Innovative Cancer Therapy Application” (hereinafter referred to as the ‘Project’) of the Japan Agency for Medical Research and Development (hereinafter referred to as the “AMED”). Chordia will receive a grant of JPY 30 million from the Project for the fiscal year ending March 2027.

2. Impact on Business Results

The impact of the above grant on our business results will be recorded as non-operating income after we receive the final notification from AMED, but will not affect our business forecast for the current fiscal year. Chordia will make a further announcement once the timing of the recognition of such non-operating income has been determined.

About Chordia Therapeutics

Chordia Therapeutics is a research and development-stage biopharmaceutical company specializing in oncology with clinical-stage assets, headquartered in Fujisawa City, Kanagawa Prefecture. Chordia’s lead asset, rogocekib (CLK inhibitor CTX-712), is under Phase 1/2 clinical study in the US. Rogocekib potentially targets the vulnerability of cancer and is expected to deliver benefits to patients of various types of cancer. In addition to rogocekib, Chordia is engaged in the research and development of several assets, including ocipumaltib (MALT1 inhibitor CTX-177), CTX-439, a CDK12 inhibitor, and GCN2 inhibitors. For more information, please visit our website <https://www.chorditherapeutics.com/en/>.